Concurrentdural and leptomeningeal metastatic carcinomatosis
are very rare and have a poor prognosis. Here we present a woman with advanced
estrogen receptor (ER) positive and progesterone receptor (PR) positive breast
cancer who presented with leptomeningeal disease. Patient underwent multi
targeted epigenetic therapies applied in a protocol called MTET. She continued
to respond to the interval treatment, which consisted only of the nutraceutical
agents. Here we discuss her case in detail and we believe that such an example
might be applied to other patients in this situation resulting clinical improvement
and less toxicity.
Kakani, C., Preeshagul, I.R., Fisher, R., et al. (2015) Management of Isolated Leptomeningeal Metastasis as the Initial and Sole Site of Recurrence in a Patient with Early-Stage Breast Cancer. International Cancer Conference Journal, 4, 101.
Mahmoud-Ahmed, A.S., Suh, J.H., Lee, S.Y., et al. (2002) Results of Whole Brain Radiotherapy in Patients with Brain Metastases from Breast Cancer: A Retrospective Study. International Journal of Radiation Oncology * Biology * Physics, 54, 810-817. https://www.ncbi.nlm.nih.gov/pubmed/12377333
Lentzsch, S., Reichardt, P., Weber, F., et al. (1999) Brain Metastases in Breast Cancer: Prognostic Factors and Management. European Journal of Cancer, 35, 580-585.
Fokstuen, T., Wilking, N., Rutqvist, L.E., et al. (2000) Radiation Therapy in the Management of Brain Metastases from Breast Cancer. Breast Cancer Research and Treatment, 62, 211-216. https://link.springer.com/article/10.1023/A:1006486423827
Rosner, D., Nemoto, T. and Lane, W.W. (1986) Chemotherapy Induces Regression of Brain Metastases in Breast Carcinoma Patients: Update Study. Cancer, 58, 832-839. http://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19860815)58:4%3C832::AID-CNCR2820580404%3E3.0.CO;2-W/full